Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert S. who wrote (7273)	9/22/1998 11:03:00 PM
From: Slugger	Read Replies (2) \| Respond to of 17367

<<While it is complete conjecture on my part, I believe the statement above suggests Neuprex is exhibiting little, if any, efficacy. If after 2 years, the trial results indicated therapeutic efficacy, the DSMB would surely not jeopardize the statistical integrity of this trial by altering it near the very end.>> If the DSMB is sure that Neuprex does not work then why are they wasting their time with all of these extra reviews? It doesn't make sense that they would ask for all these extra reviews just to look at data that isn't showing efficacy.